Raul Cordoba, Joaquín Sánchez-García, Eva Domingo-Domenech, Javier López Jiménez, Antonio Martínez Pozo, Cecilia Carpio, Ángeles Bendaña, Ana Julia González, Sonia González de Villambrosia, José Gómez Codina, Belén Navarro, Guillermo Rodríguez, Andrea Naves, Lourdes Baeza, Alejandro Martín García-Sancho
{"title":"<sup>18</sup>F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study.","authors":"Raul Cordoba, Joaquín Sánchez-García, Eva Domingo-Domenech, Javier López Jiménez, Antonio Martínez Pozo, Cecilia Carpio, Ángeles Bendaña, Ana Julia González, Sonia González de Villambrosia, José Gómez Codina, Belén Navarro, Guillermo Rodríguez, Andrea Naves, Lourdes Baeza, Alejandro Martín García-Sancho","doi":"10.1080/17474086.2024.2313457","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>An accurate assessment of tumor viability after first-line treatment is critical for predicting treatment failure in peripheral T-cell lymphomas (PTCLs). <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) positron emission tomography/computed tomography (PET/CT) has been adopted as the preferred assessment method in clinical trials, but its impact in clinical practice should be examined. This study aims to determine the prognostic significance of<sup>18</sup>F-FDG-PET/CT for survival following first-line treatment in PTCL patients.</p><p><strong>Research design and methods: </strong>Retrospective observational study including 175 patients diagnosed with PTCL between 2008 and 2013 in 13 Spanish sites.</p><p><strong>Results: </strong>Fifty patients were evaluated with<sup>18</sup>F-FDG-PET/CT following first-line therapy: 58% were<sup>18</sup>F-FDG-PET/CT-negative and 42% were<sup>18</sup>F-FDG-PET/CT-positive. Disease progression occurred in 37.9% of<sup>18</sup>F-FDG-PET/CT-negative patients and in 80.9% of<sup>18</sup>F-FDG-PET/CT-positive patients (<i>p</i> = 0.0037). Median progression-free survival and overall survival were 67 and 74 months for<sup>18</sup>F-FDG-PET/CT-negative patients, and 5 (<i>p</i> < 0.0001) and 10 months (<i>p</i> < 0.0001), respectively, in<sup>18</sup>F-FDG-PET/CT-positive patients. After multivariate analysis, only B symptoms emerged as a negative predictive factor of complete response (RR 7.08; 95% CI 1.60-31.31; <i>p</i> = 0.001).</p><p><strong>Conclusions: </strong><sup>18</sup>F-FDG-PET/CT identifies high-risk PTCL patients who will have poor prognosis and survival following first-line treatment. However, more research is needed to confirm the best treatment options for PTCL patients.</p>","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"95-100"},"PeriodicalIF":2.3000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2024.2313457","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: An accurate assessment of tumor viability after first-line treatment is critical for predicting treatment failure in peripheral T-cell lymphomas (PTCLs). 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) has been adopted as the preferred assessment method in clinical trials, but its impact in clinical practice should be examined. This study aims to determine the prognostic significance of18F-FDG-PET/CT for survival following first-line treatment in PTCL patients.
Research design and methods: Retrospective observational study including 175 patients diagnosed with PTCL between 2008 and 2013 in 13 Spanish sites.
Results: Fifty patients were evaluated with18F-FDG-PET/CT following first-line therapy: 58% were18F-FDG-PET/CT-negative and 42% were18F-FDG-PET/CT-positive. Disease progression occurred in 37.9% of18F-FDG-PET/CT-negative patients and in 80.9% of18F-FDG-PET/CT-positive patients (p = 0.0037). Median progression-free survival and overall survival were 67 and 74 months for18F-FDG-PET/CT-negative patients, and 5 (p < 0.0001) and 10 months (p < 0.0001), respectively, in18F-FDG-PET/CT-positive patients. After multivariate analysis, only B symptoms emerged as a negative predictive factor of complete response (RR 7.08; 95% CI 1.60-31.31; p = 0.001).
Conclusions: 18F-FDG-PET/CT identifies high-risk PTCL patients who will have poor prognosis and survival following first-line treatment. However, more research is needed to confirm the best treatment options for PTCL patients.
期刊介绍：
Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
